Claims for Patent: 10,344,029
✉ Email this page to a colleague
Summary for Patent: 10,344,029
Title: | Sigma-2 receptor ligand drug conjugates as antitumor compounds, methods of synthesis and uses thereof |
Abstract: | The present disclosure provides compounds of structural Formula III: ##STR00001## or a salt thereof, wherein Y is chosen from ##STR00002## Further provided are pharmaceutical compositions comprising these compounds, and methods for treating cancer, such as pancreatic cancer or synovial sarcoma, using the compounds and compositions. |
Inventor(s): | Hawkins; William (St. Louis, MO), Mach; Robert (St. Louis, MO), Spitzer; Dirk (St. Louis, MO), Vangveravong; Suwanna (St. Louis, MO), Van Tine; Brian (St. Louis, MO) |
Assignee: | Washington University (St. Louis, MO) |
Application Number: | 16/111,842 |
Patent Claims: | 1. A compound of structural Formula III: ##STR00050## or a salt thereof, wherein: each of Z.sup.1 and Z.sup.3 is independently chosen from a bond,
C.sub.1-C.sub.10alkyl, C.sub.2-C.sub.10alkyenyl, (CH.sub.2).sub.a(OCH.sub.2CH.sub.2).sub.b(CH.sub.2).sub.c--, --(CH.sub.2).sub.aN(R.sup.1)(CH.sub.2).sub.c--, --(CH.sub.2).sub.aN(R.sup.1)C(O)(CH.sub.2).sub.c--,
--(CH.sub.2).sub.a(C(O)N(R.sup.1)(CH.sub.2).sub.c--, --(CH.sub.2).sub.aN(R.sup.1)C(O)N(R.sup.1)(CH.sub.2).sub.c--; Z.sup.2 is chosen from C.sub.1-C.sub.10alkyl, C.sub.2-C.sub.10 alkenyl, (CH.sub.2).sub.a(OCH.sub.2CH.sub.2).sub.b(CH.sub.2).sub.c--,
--(CH.sub.2).sub.a(CH.sub.2CH.sub.2O).sub.b(CH.sub.2).sub.c--, --(CH.sub.2).sub.aO(CH.sub.2).sub.c--, --(CH.sub.2).sub.aS(CH.sub.2).sub.c--, --(CH.sub.2).sub.aN(R.sup.1)(CH.sub.2).sub.c--, --(CH.sub.2).sub.aN(R.sup.1)C(O)(CH.sub.2).sub.c--,
--(CH.sub.2).sub.aC(O)N(R.sup.1)(CH.sub.2).sub.c--, and --(CH.sub.2).sub.aN(R.sup.1)C(O)N(R.sup.1)(CH.sub.2).sub.c--; wherein each of Z.sup.1, Z.sup.2, and Z.sup.3 can be optionally substituted with one or more groups chosen from halo, oxo, and
C.sub.1-C.sub.10 alkyl; each R.sup.1 is independently chosen from hydrogen, C.sub.1-C.sub.10 alkyl, and C.sub.1-C.sub.10 acyl; each a and c is an integer independently chosen from 0, 1, 2, 3, and 4; each b is an integer independently chosen from 1, 2,
3, 4, 5, and 6; and Y is chosen from ##STR00051##
2. A compound or salt thereof in accordance with claim 1, wherein Z.sup.1 is C.sub.1-C.sub.10 alkyl. 3. A compound or salt thereof in accordance with claim 1, wherein Z.sup.2 is C.sub.1-C.sub.10 alkyl. 4. A compound or salt thereof in accordance with claim 1, wherein Z.sup.3 is C.sub.1-C.sub.10 alkyl. 5. A compound or salt thereof in accordance with claim 1, wherein Z.sup.1, Z.sup.2, and Z.sup.3 are each independently C.sub.1-C.sub.10 alkyl. 6. A compound or salt thereof in accordance with claim 1, wherein Y is ##STR00052## 7. A compound or salt thereof in accordance with claim 5, wherein Y is ##STR00053## 8. A compound or a salt thereof in accordance with claim 1, wherein the salt is an oxalate or a hydrochloride salt. 9. A composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier, adjuvant, or vehicle. 10. A method of treating a pancreatic cancer or a synovial sarcoma in a subject in need thereof, comprising the step of administering to the subject a therapeutically effective amount of a compound of claim 1, or a salt thereof. 11. The method according to claim 10, wherein the subject is a human. 12. A method of treating a pancreatic cancer or a synovial sarcoma in a subject in need thereof, comprising the sequential or co-administration of a compound of claim 1 or a pharmaceutically acceptable salt thereof, and an additional anticancer drug. 13. The method according to claim 12, wherein the anticancer drug is chosen from an alkylating agent, anthracycline, antimetabolite agent, crosslinking agent, DNA replication inhibitor, intercalator, microtubule disruptor, PARP inhibitor, radiomimetic agent, radiosensitizer, strand break agent, and topoisomerase II inhibitor. 14. The method according to claim 12, wherein the anticancer drug is chosen from aminoglutethimide, amsacrine, anastrozole, asparaginase, barasertib, bcg, bicalutamide, bleomycin, buserelin, busulfan, campothecin, capecitabine, carboplatin, carmustine, chlorambucil, chloroquine, cisplatin, cladribine, clodronate, colchicine, cyclophosphamide, cyproterone, cytarabine, dacarbazine, dactinomycin, daunorubicin, demethoxyviridin, dichloroacetate, dienestrol, diethylstilbestrol, docetaxel, doxorubicin, epirubicin, estradiol, estramustine, etoposide, everolimus, exemestane, filgrastim, fludarabine, fludrocortisone, fluorouracil, fluoxymesterone, flutamide, gemcitabine, genistein, goserelin, hydroxyurea, idarubicin, ifosfamide, imatinib, interferon, irinotecan, ironotecan, letrozole, leucovorin, leuprolide, levamisole, lomustine, lonidamine, mechlorethamine, medroxyprogesterone, megestrol, melphalan, mercaptopurine, mesna, metformin, methotrexate, mitomycin, mitotane, mitoxantrone, nilutamide, nocodazole, olaparib, octreotide, oxaliplatin, paclitaxel, pamidronate, pentostatin, perifosine, plicamycin, porfimer, procarbazine, raltitrexed, rituximab, sorafenib, streptozocin, sunitinib, suramin, tamoxifen, temozolomide, temsirolimus, teniposide, testosterone, thioguanine, thiotepa, titanocene dichloride, topotecan, trastuzumab, tretinoin, vinblastine, vincristine, vindesine, and vinorelbine. 15. The method of claim 12, wherein the method further comprises administering radiation therapy. 16. The method of claim 12, wherein the method further comprises administering surgery, thermoablation, focused ultrasound therapy, cryotherapy, or any combination thereof. 17. A method for treating pancreatic cancer or synovial sarcoma, comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 9 to a patient in need thereof. |
Details for Patent 10,344,029
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Recordati Rare Diseases, Inc. | ELSPAR | asparaginase | For Injection | 101063 | 01/10/1978 | ⤷ Try a Trial | 2034-04-01 |
Amgen, Inc. | NEUPOGEN | filgrastim | Injection | 103353 | 02/20/1991 | ⤷ Try a Trial | 2034-04-01 |
Amgen, Inc. | NEUPOGEN | filgrastim | Injection | 103353 | 06/28/2000 | ⤷ Try a Trial | 2034-04-01 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.